Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

October 4, 2024 | Michael Mack speaks with Stefan Anker about the outcomes and implications of the RESHAPE-HF2 trial.

With a much longer half-life than other radiotracers, flurpiridaz F-18 will boost patient access to PET imaging, one expert ...

While promising, questions remain about sustained long-term benefits of cardiac myosin inhibitors and their impact on ...